Author's response to reviews

Title: Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

Authors:

Jeetendra Eswaraka (jeetendra.eswaraka@pfizer.com)
Anand Giddabasappa (anand.giddabasappa@pfizer.com)
Guangzhou Han (guangzhou.han@pfizer.com)
Kush Lalwani (kush.lalwani@pfizer.com)
Koleen Eisele (Koleen.Eisele@pfizer.com)
Zheng Feng (Zheng.Feng@pfizer.com)
Timothy Affolter (Timothy.Affolter@pfizer.com)
James Christensen (James.Christensen@pfizer.com)
Gang Li (gang.li@pfizer.com)

Version: 4  Date: 17 September 2014

Author's response to reviews: see over
**Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer**

Dear Editor,
We thank you for the feedback. We have addressed all the edits that you requested. The corrections are highlighted in “red” in the revised version and below are the specifics. Please let us know if you have any questions.

We look forward to hear the acceptance of the manuscript for publication.

Thanks,
Anand Giddabasappa

Editorial Requests:
- Please include a separate results and conclusions section in your abstract, as per our guidelines: [http://www.biomedcentral.com/bmccancer/authors/instructions/researcharticle#formatting-abstract](http://www.biomedcentral.com/bmccancer/authors/instructions/researcharticle#formatting-abstract).
  
  **Author:** We have made the necessary changes. The current version has a section for “Conclusion”.

- Please include email addresses for all authors on your title page.
  
  **Author:** The e-mail addresses of all authors included.

- Please can you make your animal ethics statement clearer in the methods section of your manuscript, please clarify whether your study protocol was approved by the institutional animal care and use committee that you have mentioned in your manuscript.
  
  **Author:** Amended the manuscript. P-7, line 27-28 has the ethics statement.

- Please rename "Disclosure of potential conflicts of interest" as "Competing Interests"
  
  **Author:** Amended the manuscript section as “COMPETING INTERESTS”.